Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | USP9X | Q93008 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69983 | 0.83 | TDP1 (0.51) | TDP1PTGS1PTGS2NOTUMUSP9X | |
| SCHEMBL15625462 | 0.81 | TDP1 (0.38) | TDP1PTGS1PTGS2AOC3NOTUM | |
| SCHEMBL22152189 | 0.78 | TDP1 (0.39) | TDP1PTGS1PTGS2AOC3TP53 | |
| SCHEMBL13035770 | 0.78 | PTGER3 (0.42) | TDP1PTGS1PTGS2AOC3 | |
| SCHEMBL18687349 | 0.78 | MAPT (0.46) | LMNAMAPT | |
| SCHEMBL24486502 | 0.76 | PDE3B (0.51) | TDP1USP9XLMNATP53 | |
| SCHEMBL13085655 | 0.76 | AR (0.42) | TDP1 | |
| SCHEMBL18737439 | 0.76 | NOTUM (0.60) | TDP1NOTUMLMNATP53MAPT | |
| SCHEMBL70633 | 0.75 | TDP1 (0.53) | TDP1PTGS1PTGS2NOTUMSCN9A | |
| SCHEMBL13085614 | 0.75 | NPY5R (0.39) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385369-A1 | NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS | GB005 INC (US) | 2020-12-10 | — | — | US | disclosed |
| US-10562893-B2 | Benzimidazoles derivatives as Tec kinases family inhibitors | GB005, INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562893-B2 | Benzimidazoles derivatives as Tec kinases family inhibitors | BMX, TEC, BTK | TDP1 902/4885PTGS1 2671/4885PTGS2 3226/4885 |
| US-20200385369-A1 | NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS | BMX, TEC, BTK | TDP1 783/4885PTGS1 2683/4885PTGS2 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.